Files
Download Full Text (2.8 MB)
Abstract
Cancer chemotherapy results in systematic damage as the drugs used are also toxic to benign tissue. Sensitizing a cancer cell to therapy by interfering with the DNA repair mechanisms would decrease overall toxicity, as the necessary dosage of chemotherapy drugs would be lowered. The Hartman lab developed a peptide (8.6) that binds with a KD of 1 μM to the C-terminal domain of breast cancer associated protein (BRCA1), blocking homologous recombination. The crystal structure of the peptide shows the tyrosine and threonine residues are close together, suggesting that by cyclizing these positions, the peptide may already be constrained into its bound conformation. A series of dibromomethylnaphthalene linkers of various length were synthesized and cyclized through alkylation of the cysteine residues on peptide 8.6. The binding of the cyclic peptides with the BRCA1 (BRCT)2 domain will be compared to peptide 8.6 through the use of fluorescence polarization.
Publication Date
2017
Subject Major(s)
Chemistry
Keywords
BRCA1, cancer, cyclize, peptide, (BRCT)2, naphthalene, dibromomethylnaphthalene
Disciplines
Medicinal-Pharmaceutical Chemistry
Current Academic Year
Senior
Faculty Advisor/Mentor
Matthew C. T. Hartman
Rights
© The Author(s)